Aligos Therapeutics, Inc. Common Stock(ALGS)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ALGS
$10.75
—
Snapshot
$10.75
After hours
$4.25
+0.00%
- 52-Week Range
- $3.98 – $13.69
- YTD
- +17.74%
- IV Rank (30D)
- 0
- Straddle Price
- $7.03
- P/C Vol Ratio
- 0.25
- Market Cap
- $0.0B
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.71% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.71% |
| WACC | 9.63% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -284.1% |
| Book / Price | 76.0% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -1810.5% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $5.52 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.64 |
| Bollinger Width / SMA20 | 922.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, APGE, BIIB, EXEL, GILD, KRYS, MRNA, NBIX, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Model Conviction
79%
20-Day Fair Value
≈ by Aug 26, 2026
$4.46
α +5.0%
rank 98%
40-Day Fair Value
≈ by Sep 24, 2026
$4.79
α +12.7%
rank 99%
60-Day Fair Value
≈ by Oct 23, 2026
$4.71
α +10.8%
rank 99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 26.0× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.1× · 7 peers |
| Peer P/B | $21.74 | 19% | median 7.0× · 10 peers |
| Peer P/S | $2.92 | 19% | median 5.8× · 8 peers |
| Market Anchor (SMA50) | $5.52 | 61% | stability 62% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-07-28 · updated
Info
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $0.0B
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -3.44% | 6 |
| Feb | -7.95% | 6 |
| Mar | -19.76% | 6 |
| Apr | -13.00% | 6 |
| May | -4.27% | 6 |
| Jun | -8.85% | 6 |
| Jul | -0.22% | 6 |
| Aug | +11.40% | 5 |
| Sep | -14.74% | 5 |
| Oct | -7.14% | 6 |
| Nov | +33.22% | 6 |
| Dec | +11.19% | 6 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.58
SMA 50: $5.47
SMA 200: $7.47
Current: $4.25
EMA 12: $4.99
EMA 26: $5.35
MACD: -0.3566 | Signal: -0.2205
BEARISH
ADX (14): 22.50
WEAK TREND
+DI: 13.87
−DI: 29.03
Momentum Oscillators
RSI (14): 31.89
NEUTRAL
Stoch %K: 4.84
Stoch %D: 3.74
Williams %R: -91.29
Volume & Volatility
BB Upper: $7.16
BB Lower: $3.99
NEUTRAL
OBV: 14,582,970
Vol SMA 20: 312,658
Vol ROC: -12.04%
ATR: $0.49
True Range: $0.39
HV 20: 94.0%
HV 30: 84.2%
HV 60: 80.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-30T00:00:00 – 2026-07-28T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
3 of 3 under expected move
Avg Expected Move
170.02%
Avg Actual Move
9.98%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-06 | Pre-Market | 383.26% | 7.40% | 0.02x | Within |
| 2024-11-06 | Pre-Market | 71.75% | 4.70% | 0.07x | Within |
| 2025-03-10 | Pre-Market | 55.05% | 17.84% | 0.32x | Within |
Options Activity
- IV Rank (30D)
- 0
- IV Rank (7D)
- 0
- Avg IV
- 0.0%
- Straddle (30D)
- $7.03
- Straddle (7D)
- $7.03
- P/C Volume
- 0.25
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.33
- Correlation (SPY)
- 20.6%
- R²
- 0.04
- Ann. Volatility
- 82.0%
- SPY Volatility
- 12.7%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 10,252,144 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Insider Activity
Latest: 2026-06-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Margarita Chavez | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-06-29 | Bridget A Martell | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-06-29 | Heather Preston | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-06-29 | Carole Nuechterlein | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-06-29 | Peter Hirth | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-06-29 | James Paul Scopa | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2026-03-11 | Julian A. Symons | See Remarks | Grant (A) | +23,310 opt | — | EDGAR | |
| 2026-03-11 | Nikhil Aneja | Principal Accounting Officer | Grant (A) | +9,450 opt | — | EDGAR | |
| 2026-03-11 | LAWRENCE BLATT | President and CEO | Grant (A) | +105,840 opt | — | EDGAR | |
| 2026-03-11 | Lesley Ann Calhoun | See Remarks | Grant (A) | +37,485 opt | — | EDGAR | |
| 2025-07-18 | LAWRENCE BLATT | President and CEO | Grant (A) | +179,800 opt | — | EDGAR | |
| 2025-07-18 | Julian A. Symons | See Remarks | Grant (A) | +16,000 opt | — | EDGAR | |
| 2025-07-18 | Lesley Ann Calhoun | See Remarks | Grant (A) | +40,185 opt | — | EDGAR | |
| 2025-06-26 | Margarita Chavez | Director | Grant (A) | +5,860 opt | — | EDGAR | |
| 2025-06-26 | Bridget A Martell | Director | Grant (A) | +5,860 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
11 insiders · @ $4.25
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Carole Nuechterlein | Director | 441,038 | $1.87M | $6.00M | 9 | 2026-06-29 |
| 2 | Versant Vantage I, L.P. | 10%+ Owner | 123,694 | $525.7K | $6.00M | 1 | 2020-10-20 |
| 3 | Novo Holdings A/S | 10%+ Owner | 96,583 | $410.5K | $3.00M | 1 | 2020-10-22 |
| 4 | Vivo Capital Surplus Fund VIII, L.P. | 10%+ Owner | 96,373 | $409.6K | $24.75M | 1 | 2020-10-20 |
| 5 | LAWRENCE BLATT | President and CEO | 78,440 | $333.4K | $0 | 13 | 2026-03-11 |
| 6 | Thomas Woiwode | Director | 58,495 | $248.6K | $3.00M | 5 | 2022-06-27 |
| 7 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%+ Owner | 53,402 | $227.0K | $0 | 1 | 2020-10-22 |
| 8 | Leonid Beigelman | President | 41,622 | $176.9K | $0 | 5 | 2023-03-17 |
| 9 | Julian A. Symons | See Remarks | 15,763 | $67.0K | $0 | 12 | 2026-03-11 |
| 10 | Lucinda Y. Quan | See Remarks | 15,363 | $65.3K | $0 | 6 | 2023-09-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 0.8 |
| P/S Ratio | 5.4 |
| EV/EBITDA | 0.1 |
| TTM Revenue | $0.0B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-8.79 |
| ROE | -284.1% |